# KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

> **NCT06384976** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kyverna Therapeutics** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis
- MS

## Interventions

- **BIOLOGICAL:** KYV-101
- **DRUG:** Standard lymphodepletion regimen
- **DRUG:** Anti-CD20 mAB

## Key facts

- **NCT ID:** NCT06384976
- **Lead sponsor:** Kyverna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2027-04
- **Final completion:** 2029-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06384976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06384976, "KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06384976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*